Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (12,580,209)	$ (8,325,488)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	163,262	46,945
Warranty provision	30,364	13,495
Inventory write-off	(68,108)	(193,506)
Non-cash lease expense	121,843	80,069
Share-based compensation	2,236,743	1,536,096
Debt forgiveness income	(416,683)	0
Non-cash interest expense	2,321	0
Common shares issued for services	0	102,600
Provision for doubtful accounts	10,140	0
Changes in assets and liabilities:
Accounts receivable	(1,685,727)	(190,951)
Inventories	(342,741)	(1,892,768)
Prepaid expenses and other current assets	(508,498)	(136,084)
Accounts payable	825,382	174,052
Operating lease liability	(128,132)	(62,851)
Customer deposits	(341,629)	343,724
Accrued liabilities and other	492,564	112,346
Deferred compensation	0	(96,000)
Warranty settlement	3,853	0
Deferred revenue	(1,669)	2,684
Net cash used in operating activities	(12,186,924)	(8,485,637)
Cash Flows From Investing Activities:
Purchase of short-term investments	(34,979,511)	0
Proceeds from maturities of short-term investments	10,000,000	0
Capital expenditures for property and equipment	(248,897)	(256,742)
Investment in patents and trademarks	(128,914)	(114,274)
Purchase of intangible assets	(543,563)	0
Business acquisition	(210,000)	0
Long-term deposits	0	(11,169)
Net cash used in investing activities	(26,110,885)	(382,185)
Cash Flows From Financing Activities:
Sale of common stock and warrants	12,400,002	12,499,994
Offering costs paid on sale of stock and warrants	(732,796)	(1,148,780)
Proceeds from exercise of warrants	26,190,483	2,112,117
Offering costs paid on exercise of warrants	(1,016,645)	(28,666)
Proceeds from exercise of stock options	705,350	58,125
Proceeds from bank note	414,362	0
Net cash provided by financing activities	37,960,756	13,492,790
Net increase (decrease) in cash and cash equivalents	(337,053)	4,624,968
Cash and cash equivalents, beginning of period	16,983,864	12,358,896
Cash and cash equivalents, end of period	16,646,811	16,983,864
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Business acquisition liability	297,500	0
Business acquisition cost in deferred revenue	15,000	0
Change in unrealized gain on short-term investments	14,849	0
Right-of-use assets and liabilities recorded during period	0	341,000
Issuance costs relating to warrants issued to public offering selling agent	$ 0	$ 205,894